drugset / Trial / NCT02681809
A Study to Evaluate the Efficacy and Safety of Ocriplasmin in Inducing Total PVD in Subjects With NPDR
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study is to assess the efficacy and safety of up to 3 intravitreal injections of ocriplasmin (0.0625mg or 0.125mg), in subjects with moderate to very severe non-proliferative diabetic retinopathy (NPDR), to induce total posterior vitreous detachment (PVD) in order to reduce the risk of disease progression to proliferative diabetic retinopathy (PDR).
Timeline
- Start
- 2015-12
- Primary completion
- 2019-11-18
- Completion
- 2019-11-18
Outcome
Outcome not reported
Stopped (Enrollment): “Slow recruitment rate”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ocriplasmin | Protein / enzyme biologic | 0.0625 mg | Intravitreal |
| Subject | Ocriplasmin | Protein / enzyme biologic | 0.125 mg | Intravitreal |